Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023)

Summit Therapeutics (SMMT) posted quarterly Asset Writedowns and Impairment of $474000.0 for Q1 2023, down 94.4% on a QoQ basis from $8.5 million in Q4 2022.

Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends

Summit Therapeutics (SMMT) has reported Asset Writedowns and Impairment for 3 consecutive years, with $474000.0 the latest figure, recorded in Q1 2023.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $474000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $474000.0 (down 94.4% YoY) and the FY2023 annual result came in at $474000.0, down 94.4% from the prior year.
  • Asset Writedowns and Impairment fell to $474000.0 in Q1 2023 per SMMT's latest filing, from $8.5 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for SMMT reached as high as $8.5 million in Q4 2022 and fell as low as $474000.0 in Q1 2023.
  • A 3-year average of $3.3 million and a median of $859000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Summit Therapeutics 10.29 Bn 9.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2023 474,000.00
Mar 31, 2023 474,000.00
Dec 31, 2022 8.47 Mn
Dec 31, 2022 8.47 Mn
Sep 30, 2020 859,000.00
Sep 30, 2020 859,000.00